Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population

Journal of Managed Care Pharmacy

Volumn 21, Issue 4, 2015, Pages 318-328

  Curtis, Jeffrey R ^a   Chastek, Benjamin ^b   Becker, Laura ^b   Quach, Caroleen ^c   Harrison, David J ^e   Yun, Huifeng ^a   Joseph, George J ^d   Collier, David H ^e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b OPTUM   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d SANOFI   (France)

^e AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE INCREASE; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; UNITED STATES; ADOLESCENT; ARTHRITIS, RHEUMATOID; COST BENEFIT ANALYSIS; ECONOMICS; INSURANCE; PROCEDURES; YOUNG ADULT; ALGORITHM; DATA BASE; HEALTH CARE COST; MANAGED CARE; OUTCOME ASSESSMENT; SENSITIVITY ANALYSIS;

ADOLESCENT; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; YOUNG ADULT;

EID: 84930149807     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2015.21.4.318     Document Type: Article

References (41)

1. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15-25. Available at: http://onlinelibrary.wiley. com/doi/10.1002/art.23177/abstract. Accessed February 18, 2015.
2. Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M. Societal cost of rheumatoid arthritis patients in the U.S. Curr Med Res Opin. 2010;26(1):77-90.
3. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic diseasemodifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762-84. Available at: http://onlinelibrary.wiley.com/doi/10.1002/art.23721/abstract. Accessed February 18, 2015.
4. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-39. Available at: http://onlinelibrary.wiley.com/doi/10.1002/acr.21641/abstract. Accessed February 18, 2015.
5. ORENCIA (abatacept) for injection for intravenous use; for injection for subcutaneous use. Bristol-Myers Squibb Company. Revised December 2014. Available at: http://packageinserts.bms.com/pi/pi_orencia.pdf. Accessed February 18, 2015.
6. HUMIRA (adalimumab) injection, for subcutaneous use. Abbott Laboratories. Revised December 2014. Available at: http://www.rxabbott. com/pdf/humira.pdf. Accessed February 18, 2015.
7. CIMZIA (certolizumab pegol) for injection, for subcutaneous use; injection, for subcutaneous use. UCB, Inc. Revised October 2013. Available at:http://www.cimzia.com/assets/pdf/Prescribing_Information.pdf. Accessed February 18, 2015.
8. Enbrel (etanercept) solution for subcutaneous use. Immunex Corporation. Revised November 2013. Available at: http://pi.amgen.com/united_states/enbrel/derm/enbrel_pi.pdf. Accessed February 18, 2015.
9. SIMPONI (golimumab) injection, for subcutaneous use. Janssen Biotech, Inc. Revised December 2014. Available at: http://www.simponi.com/shared/product/simponi/prescribing-information.pdf. Accessed March 9, 2015.
10. REMICADE (infliximab) lyophilized concentrate for injection, for intravenous use. Centocor Ortho Biotech, Inc. Revised January 2015. Available at: http://www.remicade.com/hcp/remicade/assets/hcp_ppi.pdf. Accessed February 18, 2015.
11. ACTEMRA (tocilizumab) injection, for intravenous use; injection, for subcutaneous use. Genentech, Inc. Revised November 2014. Available at:http://www.gene.com/download/pdf/actemra_prescribing.pdf. Accessed February 18, 2015.
12. Estellat C, Ravaud P. Lack of head-to-head trials and fair control arms:randomized controlled trials of biologic treatment for rheumatoid arthritis. Arch Intern Med. 2012;172(3):237-44. Available at: http://archinte.jamanetwork. com/article.aspx?articleid=1108719. Accessed February 18, 2015.
13. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67(8):1096-103. Available at: http://ard.bmj.com/content/67/8/1096. long. Accessed February 18, 2015.
14. Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013;65(1):28-38. Available at: http://onlinelibrary.wiley.com/doi/10.1002/art.37711/abstract. Accessed February 18, 2015.
15. Kume K, Amano K, Yamada S, Hatta K, Ohta H, Kuwaba N. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J Rheumatol. 2011;38(10):2169-71.
16. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508-19. Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa1112072. Accessed February 18, 2015.
17. Greenberg JD, Reed G, Decktor D, et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the U.S. CORRONA registry. Ann Rheum Dis. 2012;71(7):1134-42.
18. Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541-50.
19. Strand V, Sokolove J. Randomized controlled trial design in rheumatoid arthritis: the past decade. Arthritis Res Ther. 2009;11(1):205. Available at:http://arthritis-research.com/content/11/1/205. Accessed February 18, 2015.
20. Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission. J Rheumatol. 2003;30(6):1138-46.
21. Brass EP. The gap between clinical trials and clinical practice: the use of pragmatic clinical trials to inform regulatory decision making. Clin Pharmacol Ther. 2010;87(3):351-55.
22. Shaver TS, Anderson JD, Weidensaul DN, et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol. 2008;35(6):1015-22.
23. Curtis JR, Baddley JW, Yang S, et al. Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. Arthritis Res Ther. 2011;13(5):R155. Available at: http://arthritis-research.com/content/13/5/R155. Accessed February 18, 2015.
24. Curtis JR, Chastek B, Becker L, et al. Further evaluation of a claimsbased algorithm to determine the effectiveness of biologics for rheumatoid arthritis using commercial claims data. Arthritis Res Ther. 2013;15(2):404. Available at: http://arthritis-research.com/content/15/2/404. Accessed February 18, 2015.
25. Basu A, Rathouz PJ. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics. 2005;6(1):93-109. Available at: http://biostatistics.oxfordjournals. org/content/6/1/93.long. Accessed February 18, 2015.
26. Gilbert TD Jr, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord. 2004;5(1):36. Available at:http://www.biomedcentral.com/1471-2474/5/36. Accessed February 18, 2015.
27. Agarwal SK, Maier AL, Chibnik LB, et al. Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum. 2005;53(6):872-78. Available at: http://onlinelibrary.wiley.com/doi/10.1002/art.21582/abstract. Accessed February 18, 2015.
28. Berger A, Edelsberg J, Li TT, Maclean JR, Oster G. Dose intensification with infliximab in patients with rheumatoid arthritis. Ann Pharmacother. 2005;39(12):2021-25.
29. Etemad L, Yu EB, Wanke LA. Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Manag Care Interface. 2005;18(4):21-27.
30. Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin. 2008;24(8):2229-40.
31. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460-68. Available at: http://jama.jamanetwork.com/article. aspx?articleid=896649. Accessed February 18, 2015.
32. Moots RJ, Haraoui B, Matucci-Cerinic M, et al. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol. 2011;29(1):26-34.
33. Bonafede MM, Gandra SR, Fox KM, Wilson KL. Tumor necrosis factor blocker dose escalation among biologic naive rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation. J Med Econ. 2012;15(4):635-43.
34. Schabert VF, Bruce B, Ferrufino CF, et al. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study. Curr Med Res Opin. 2012;28(4):569-80.
35. Donahue KE, Jonas D, Hansen RA, et al. Drug therapy for rheumatoid arthritis in adults: an update. Comparative Effectiveness Review No. 55. (Prepared by RTI-UNC Evidence-based Practice Center under Contract No. 290-02-0016-I.) AHRQ Publication No. 12-EHC025-EF. Rockville, MD: Agency for Healthcare Research and Quality. April 2012. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/203/1044/CER55_DrugTherapiesforRheumatoidArthritis_FinalReport_20120618.pdf. Accessed February 18, 2015.
36. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727-35.
37. Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum. 1998;41(9):1564-70.
38. Curtis JR, Schabert VF, Harrison DJ, et al. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims. Clin Ther. 2014;36(7):996-1004.
39. Curtis JR, Schabert VF, Yeaw J, et al. Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis. J Med Econ. 2014;17(8):555-66.
40. Curtis JR, Chen L, Luijtens K, et al. Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data. Arthritis Rheum. 2011;63(8):2203-08. Available at: http://onlinelibrary.wiley. com/doi/10.1002/art.30387/abstract. Accessed February 18, 2015.
41. Pavelka K, Jarosova K, Suchy D, et al. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. Ann Rheum Dis. 2009;68(8):1285-89. Available at: http://ard.bmj.com/content/68/8/1285.long. Accessed February 18, 2015.